Noven Announces 2007 Annual Meeting Results

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the results of its 2007 Annual Meeting of Stockholders. At the meeting, held May 18, 2007, stockholders elected the following persons to the Noven Board of Directors:

  • Sidney Braginsky – President & Chief Executive Officer, Atropos Technology Inc.;
  • John G. Clarkson, M.D. – Executive Director of the American Board of Ophthalmology and Dean Emeritus and Professor of Ophthalmology, University of Miami Miller School of Medicine;
  • Donald A. Denkhaus – Executive Chairman, TM Systems, LLC;
  • Pedro P. Granadillo – Global Manufacturing & Human Resources (Retired), Eli Lilly & Company;
  • Robert G. Savage – Worldwide Chairman, Pharmaceutical Group (Retired), Johnson & Johnson;
  • Robert C. Strauss – Noven’s President, Chief Executive Officer & Chairman; and
  • Wayne P. Yetter – Chief Executive Officer, Verispan LLC.

Stockholders also ratified the appointment of Deloitte & Touche LLP Stockholders also approved an amendment to Noven’s 1999 Long-Term Incentive Plan, as well as the material terms of the performance goals under that Plan. Stockholders also ratified the appointment of Deloitte & Touche LLP as Noven’s independent registered public accounting firm for 2007. At the meeting, Robert Strauss made a presentation regarding Noven’s business and prospects, a replay of which will be available at www.noven.com for at least two weeks.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries and include Vivelle-Dot® (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916